亚博网网址B3C新闻专线 B3C新闻专线最新生物科技新闻(简称)亚博网网址//www.whupabstinence.com/ 2020年6月17日星期三23:09:02 +0200 FeedCreator 1.8.3 (obRSS 3.3.10) //www.whupabstinence.com/images/feed-icon-28x28.png 亚博网网址B3C新闻专线 //www.whupabstinence.com/ B3C新闻专线最新生物科技新闻(简称)亚博网网址 EN-GB arivis推出多用户VR对于容积成像 //www.whupabstinence.com/202006162082/arivis-unveils-multiuser-vr-for-volumetric-imaging.html

MUNICH, Germany, June 16, 2020 / B3C newswire / -- arivis , a software provider for visualization, analysis, and management of big image data, announces the new VisionVR 3.2, which now enables users to simultaneously experience 3D and 4D image volumes and surfaces in an immersive environment.

Meet collaborators in VR

Users of arivis VisionVR can meet in a virtual environment and work together on the same dataset. The new collaboration functionality includes:

  • Movement, scaling and clipping of data volumes occur in real time for all participants.
  • Intranet or Internet is configurable.
  • Users see each other’s position, view direction, and hand movement.
  • Collaborators ... 2020年6月16日星期二000:00 +0200 //www.whupabstinence.com/202006162082/arivis-unveils-multiuser-vr-for-volumetric-imaging.html 在2020年第二届AACR虚拟年会上,SOTIO将展示关于IL-15超激动剂SO-C101的临床前数据 //www.whupabstinence.com/202006152081/sotio-to-present-new-preclinical-data-on-il-15-superagonist-so-c101-at-the-2020-aacr-virtual-annual-meeting-ii.html

    PRAGUE, Czech Republic, June 15, 2020 / B3C newswire / -- SOTIO , a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.

    Poster presentation details

    Poster title: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent mannerSO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
    Abstract: 6686 / 2
    Session: Session PO.IM02.20 - Immunomodulatory ... 星期一,2020年6月15日14:00:00 +0200 //www.whupabstinence.com/202006152081/sotio-to-present-new-preclinical-data-on-il-15-superagonist-so-c101-at-the-2020-aacr-virtual-annual-meeting-ii.html ZZ生物科技宣布FDA对卒中项目快速跟踪指定 //www.whupabstinence.com/202006122080/zz-biotech-announces-fda-fast-track-designation-for-stroke-program.html

    HOUSTON, USA, June 12, 2020 / B3C newswire / -- ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program.

    ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays a role in the regulation of blood clotting and inflammation. In animal models of stroke, 3K3A-APC has helped prevent bleeding caused by tPA, the only drug currently indicated for the treatment of acute ischemic stroke. The ... 星期五,2020年6月12日09:30:00 +0200 //www.whupabstinence.com/202006122080/zz-biotech-announces-fda-fast-track-designation-for-stroke-program.html 眼科数字医疗:Implandata推出EYEMATE IOP跟踪服务进行远程监控和改进青光眼护理 //www.whupabstinence.com/202006082079/ophthalmic-digital-health-implandata-launches-eyemate-iop-tracking-service-for-remote-monitoring-and-improved-glaucoma-care.html

    Keeping patients safe and improving quality of care – anytime and anywhere

    HANNOVER, Germany, June 08, 2020 / B3C newswire / -- Implandata Ophthalmic Products GmbH , a digital health company, announces the launch of its web-based EYEMATE IOP-Tracking Service for remote monitoring and management of glaucoma care. The EYEMATE IOP-Tracking Service is the world’s first solution to provide eye doctors with Intra-Ocular Pressure (IOP) measurements collected 24/7/365 under patients’ normal life conditions.

    Prof. Kaweh Mansouri, MD, Ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland and Chief Medical Officer of Implandata explains: “Remote IOP monitoring provides immediate alert in case the therapy ... 星期一,2020年6月8日09:30:00 +0200 //www.whupabstinence.com/202006082079/ophthalmic-digital-health-implandata-launches-eyemate-iop-tracking-service-for-remote-monitoring-and-improved-glaucoma-care.html Cellbox Solutions任命赫伯特·米勒-哈特曼博士为研发总监 //www.whupabstinence.com/202006052078/cellbox-solutions-appoints-dr-herbert-mueller-hartmann-as-head-of-research-and-development.html

    KIEL, Germany, June 05, 2020 / B3C newswire / -- Effective today, Cellbox Solutions GmbH announces the appointment of former Head of Biosolutions R&D from Lonza Pharma and Biotech, Dr. Herbert A. Mueller-Hartmann, as the new Head of Research and Development. Dr. Mueller-Hartmann will be continuing on the successful work of Dr. Hans-Otto Nagels.

    Wolfgang Kintzel, CEO of Cellbox Solutions, commented: “As Cellbox Solutions enters into its next phase of growth, it is with great pleasure that we announce Herbert as our new Head of R&D. Herbert brings with him extensive experience and a strong record for developing significant ... 周五,2020年6月5日10:30:00 +0200 //www.whupabstinence.com/202006052078/cellbox-solutions-appoints-dr-herbert-mueller-hartmann-as-head-of-research-and-development.html 德尔塔4宣布与药物发现平台取得的结果 //www.whupabstinence.com/202006022077/delta-4-announces-results-achieved-with-drug-discovery-platform.html

    • <在罕见肾脏疾病的药物候选强>正临床前数据
    • 平台提供有前途的COVID-19的候选药物 <的短列表/ UL>

      <强>
      奥地利维也纳,2020年6月2日 / <强> B3C通讯社/ - 德尔塔4 ,利用其成熟的数字药物发现平台,以确定批准的药物新适应症一家生物技术公司,今天公布最新研究成果两种药物发现和实现发展计划。在其带动计划,该计划旨在发展为局灶节段性肾小球硬化(FSGS),影响儿童和成人的一种罕见的肾脏疾病治疗,德尔塔4号结束的临床前开发阶段可喜的成果。本公司发起的专利申请,是... 星期二,2020年6月2日14:00:00 +0200 //www.whupabstinence.com/202006022077/delta-4-announces-results-achieved-with-drug-discovery-platform.html 维特尔赢得了Axia最佳管理公司奖 //www.whupabstinence.com/202005282076/vetter-wins-axia-best-managed-companies-award.html < p > < a href = " https://www.vetter-pharma.com/en " target = "平等" rel = "跟随没有noopener " > < / > < / p > < ul > <李> <强>密封质量优秀企业管理< /强> < /李> <李> <强>分析领域的战略,创新,企业文化和金融< /强> < /李> <李> <强>综合三级申请过程< /强> < /李> < / ul > < p > <强> RAVENSBURG,德国5月28日2020 / B3C newswire / --
      A look at vital figures makes it clear that Vetter is a very successful, globally active Contract Development and Manufacturing Organization (CDMO). Over the last ten years, the company has more than doubled its annual sales revenues to approximately 670 million euros while the number of staff members has grown to 5,000. Now, there is further proof. The family-owned company has been awarded the Axia Best ... 2020年5月28日星期四16:15:00 +0200 //www.whupabstinence.com/202005282076/vetter-wins-axia-best-managed-companies-award.html Covid-19疫苗,用于使用13000个剂量的IRBM的问世宣布制造阶段中由牛津大学2/3临床试验 //www.whupabstinence.com/202005282075/irbm-s-advent-announces-manufacture-of-13-000-doses-of-covid-19-vaccine-for-use-in-phase-2-3-clinical-trials-by-the-university-of-oxford.html

      POMEZIA, Italy, May 28, 2020 / B3C newswire / -- Advent Srl , an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222). The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial   COV002 by the University of Oxford, England.

      Following a long history of partnership, including the announcement on 7 February of an agreement between The Jenner Institute and IRBM’s Advent to manufacture ChAdOx1 nCoV-19, Advent has now manufactured ... 2020年5月28日星期四000:00 +0200 //www.whupabstinence.com/202005282075/irbm-s-advent-announces-manufacture-of-13-000-doses-of-covid-19-vaccine-for-use-in-phase-2-3-clinical-trials-by-the-university-of-oxford.html SeraNovo与Carna Biosciences签订了第二份许可协议,开发Carna激酶抑制剂的口服制剂 //www.whupabstinence.com/202005262074/seranovo-enters-into-a-second-license-agreement-with-carna-biosciences-for-development-of-oral-formulation-of-carna-s-kinase-inhibitor.html

      <强>莱顿,荷兰,May 26, 2020 / B3C newswire / -- SeraNovo B.V. today announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilising its proprietary Deep Eutectic Solvent (DES) formulation platform , SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and ... 2020年5月26日星期二000:00 +0200 //www.whupabstinence.com/202005262074/seranovo-enters-into-a-second-license-agreement-with-carna-biosciences-for-development-of-oral-formulation-of-carna-s-kinase-inhibitor.html 舒文宣布发表同行评议的数据,证明其突破性的子痫前期检测设备在未选定女性中的潜力 //www.whupabstinence.com/202005212073/shuwen-announces-peer-reviewed-publication-of-data-demonstrating-the-potential-of-its-breakthrough-preeclampsia-detection-device-in-unselected-women。HTML

      <强> DEQING,中国,5月21日,2020 / B3亚博网网址C通讯社/ - 叔文生物有限公司,在创新诊断一家中国的领导人今天公布的数据凸显当中谁是住院的妇女迅速地诊断先兆子痫的突破点 - - 关心测试的潜在的同行评审的出版物。该文件题为“妊娠筛查先兆子痫用尿点的护理测试错误折叠的蛋白的”,作者是来自中国医科大学的附属盛京医院和哥伦比亚大学医学中心在纽约合作者和演示测试在较高的水平,以检测先兆子痫的能力在送往医院因任何原因的妇女的准确性。调查结果包括... 周四2020 11:00:00 +0200 5月21日 //www.whupabstinence.com/202005212073/shuwen-announces-peer-reviewed-publication-of-data-demonstrating-the-potential-of-its-breakthrough-preeclampsia-detection-device-in-unselected-women。HTML 气道治疗公司和Celonic集团合作生产AT-100作为冠状病毒的新候选者 //www.whupabstinence.com/202005202072/airway-therapeutics-and-celonic-group-collaborate-to-produce-at-100-as-promising-new-candidate-for-coronavirus.html
      < a href = " https://www.airwaytherapeutics.com " target = "平等" rel = "跟随没有noopener " > < / >, < / td > < / tr > < / tbody > < /表> < p > <强> - 100生产预计将在6月< /强> < / p > < p > <强>辛辛那提,哦,美国和巴塞尔瑞士,5月20日2020 / B3C新闻专线/ < /强>气道疗法,Inc .)、生物制剂的生物制药公司开发一个新类打破这个循环的损伤和炎症患者呼吸疾亚博网网址病和炎症性疾病,and Celonic Group , a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate ... 2020年5月20日星期三1500:00 +0200 //www.whupabstinence.com/202005202072/airway-therapeutics-and-celonic-group-collaborate-to-produce-at-100-as-promising-new-candidate-for-coronavirus.html BC平台和Kaiser Permanente的赢2020微软精密医药卫生合作创新奖 //www.whupabstinence.com/202005192071/bc-platforms-and-kaiser-permanente-win-2020-microsoft-health-innovation-award-for-precision-medicine-collaboration.html

      < a href="https://www.bcplatforms.com/" target="_blank" rel="Follow No noopener">< p><瑞士苏黎世和美国波士顿,5月19日,2020 / B3C newswire / -- BC Platforms  and Kaiser Permanente today announced they are winners of the 2020 Microsoft Health Innovation Award in the Reimagine Health Category for enabling a unique way of pairing clinical and genomic data on the same platform to advance precision medicine capabilities.

      BC Platforms and Kaiser Permanente collaborated using Microsoft’s Azure cloud platform to safely and securely integrate data from multiple research centers into a single virtual biobank framework.

      The awards recognize health organizations and their technology solution partners for using Microsoft’s technology solutions in innovative ways ... 2020年5月19日星期二1800:00 +0200 //www.whupabstinence.com/202005192071/bc-platforms-and-kaiser-permanente-win-2020-microsoft-health-innovation-award-for-precision-medicine-collaboration.html FluoGuide A/S被独立IPO指南评为2019年度最佳IPO //www.whupabstinence.com/202005182070/fluoguide-a-s-is-awarded-best-ipo-in-2019-by-the-independent-ipo-guide.html
       

      COPENHAGEN, Denmark, May 18, 2020 / B3C newswire / -- Affärsvärlden’s IPO Guide announced that FluoGuide A/S (“FluoGuide”) won the 2019 share price development award in the micro-cap category and also received the honorary quality award. The IPO Guide is an independent analysis group that has reviewed all Swedish IPOs since 2017.

      FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001 , is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it ... 2020年5月18日星期一10:00 00 +0200 //www.whupabstinence.com/202005182070/fluoguide-a-s-is-awarded-best-ipo-in-2019-by-the-independent-ipo-guide.html Clinigen与Xeris Pharmaceuticals签署独家协议,在美国以外地区供应和分销Gvoke™ //www.whupabstinence.com/202005142069/clinigen-signs-exclusive-agreement-with-xeris-pharmaceuticals-to-supply-and-distribute-gvoke-outside-the-us.html

      <强>伯顿ON-Trent,英国,2020年5月14日/美通社B3C / -亚博网网址 Clinigen集团公司 (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Xeris Pharmaceuticals, Inc. (NASDAQ: XERS, ‘Xeris’) to manage the supply and distribution of Gvoke™ (glucagon) injection, a treatment for diabetes, outside the US.

      Under the terms of the supply and distribution agreement with Xeris, Clinigen will provide physicians and pharmacists with access to Gvoke™ on an unlicensed, on-demand basis for patients around the world, excluding the US.

      Gvoke™ (glucagon) injection, is a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe ... 2020年5月14日星期四000:00 +0200 //www.whupabstinence.com/202005142069/clinigen-signs-exclusive-agreement-with-xeris-pharmaceuticals-to-supply-and-distribute-gvoke-outside-the-us.html 生物医学X研究所推出快速抗病毒反应平台,以预防未来的大流行 //www.whupabstinence.com/202005132068/biomed-x-institute-launches-rapid-antiviral-response-platform-to-prevent-future-pandemics.html < p > < a href = " https://www.bio.mx/ " target = "平等" rel = "跟随没有noopener " > < / > < / p > < ul > <李> <强>海德堡独立研究所、德国,开发新的抗病毒药物发现的阿森纳,开发和推出工具对任何未来这将使一个有效的反应病毒威胁在不到6个月< /强> < /李> <李> < >强劲快速的抗病毒反应平台建立的一个国际财团的制药公司,基金会,public health organizations, government agencies, and healthcare funds

      HEIDELBERG, Germany, May 13, 2020 / B3C newswire / -- BioMed X , an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation, announces today the launch of its new ... 2020年5月13日星期三10:00:00 +0200 //www.whupabstinence.com/202005132068/biomed-x-institute-launches-rapid-antiviral-response-platform-to-prevent-future-pandemics.html